Date: 2015-06-26
Type of information: Nomination
Compound:
Company: Aduro Biotech (USA - CA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 26, 2015, Aduro Biotech announced the appointment of Stephen Sherwin, M.D., to the company\'s board of directors. The addition of Dr. Sherwin increases the number of directors from six to seven. Dr. Sherwin currently divides his time between advisory work in the life science industry, patient care and teaching medical oncology. He is a clinical professor of medicine at the University of California, San Francisco, and a volunteer attending physician in hematology-oncology at San Francisco General Hospital. He currently serves as a director at Biogen, Neurocrine Biosciences, Rigel Pharmaceuticals, Verastem and Vical and is an advisor to oncology-focused life science companies. Previously, Dr. Sherwin was chairman and chief executive officer of Cell Genesys, an immuno-oncology company, from 1990 until the company\'s merger in 2009 with BioSante Pharmaceuticals, (now ANI Pharmaceuticals). He was also a co-founder and chairman of Abgenix, an antibody company, which was acquired by Amgen in 2006, and co-founder and chairman of Ceregene, a gene therapy company acquired by Sangamo Biosciences in 2013. Earlier in his career, Dr. Sherwin was vice president of clinical research at Genentech. Dr. Sherwin also served on the board of directors of the Biotechnology Industry Organization from 2001 to 2014 and as chairman of the organization from 2009 to 2011 and was a member of the President\'s Council of Advisors in Science and Technology Working Group on Drug Development from 2011 to 2013. Dr. Sherwin holds a B.A. in biology from Yale University, where he graduated summa cum laude, and an M.D. from Harvard Medical School. He is board-certified in internal medicine and medical oncology and a fellow of the American College of Physicians.
Financial terms:
Latest news:
